




Instance: composition-en-20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: CompositionUvEpi
Title: "Composition for samsca Package Leaflet"
Description:  "Composition for samsca Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1eb1b528e890c79700aede7e878d280f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - samsca"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Samsca is and what it is used for  </li>
<li>What you need to know before you take Samsca  </li>
<li>How to take Samsca  </li>
<li>Possible side effects  </li>
<li>How to store Samsca </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What samsca is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What samsca is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Samsca, which contains the active substance tolvaptan, belongs to a group of medicines called 
vasopressin antagonists. Vasopressin is a hormone that helps prevent the loss of water from the body 
by reducing urine output. Antagonist means that it prevents vasopressin having its effect on water 
retention. This leads to a reduction in the amount of water in the body by increasing urine production 
and as a result it increases the level or concentration of sodium in your blood. </p>
<p>Samsca is used to treat low serum sodium levels in adults. You have been prescribed this medicine 
because you have a lowered sodium level in your blood as a result of a disease called  syndrome of 
inappropriate antidiuretic hormone secretion  (SIADH) where the kidneys retain too much water. This 
disease causes an inappropriate production of the hormone vasopressin which has caused the sodium 
levels in your blood to get too low (hyponatremia). That can lead to difficulties in concentration and 
memory, or in keeping your balance. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Samsca 
* if you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in 
section 6) or if you are allergic to benzazepine or benzazepine derivatives (e.g., benazepril, 
conivaptan, fenoldopam mesylate or mirtazapine) 
* if your kidneys do not work (no urine production) 
* if you have a condition which increases the salt in your blood ( hypernatremia ) 
* if you have a condition which is associated with a very low blood volume 
* if you do not realise when you are thirsty 
* if you are pregnant 
* if you are breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Samsca: 
* if you cannot drink enough water or if you are fluid restricted 
* if you have difficulties in urination or have an enlarged prostate 
* if you suffer from liver disease 
* if you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine 
derivatives (e.g., benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the 
other ingredients of this medicine  (listed in section 6). 
* if you suffer from a kidney disease called autosomal dominant polycystic kidney disease 
(ADPKD) 
* if you have diabetes. </p>
<p>Drinking enough water 
Samsca causes water loss because it increases your urine production. This water loss may result in side 
effects such as dry mouth and thirst or even more severe side effects like kidney problems (see 
section 4). It is therefore important that you have access to water and that you are able to drink 
sufficient amounts when you feel thirsty. </p>
<p>Children and adolescents 
Samsca is not suitable for children and adolescents (under age 18). </p>
<p>Other medicines and Samsca 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This includes all medicines obtained without a prescription. </p>
<p>The following medicines may increase the effect of this medicine: 
* ketoconazole (against fungal infections), 
* macrolide antibiotics, 
* diltiazem (treatment for high blood pressure and chest pain), 
* other products which increase the salt in your blood or which contain large amounts of salt. </p>
<p>The following medicines may lower the effect of this medicine: 
* barbiturates (used to treat epilepsy/seizures and some sleep disorders), 
* rifampicin (against tuberculosis). </p>
<p>This medicine may increase the effect of the following medicines: 
* digoxin (used for treatment of irregularities of heartbeat and heart failure), 
* dabigatran etexilate (used to thin the blood), 
* metformin (used to treat diabetes), 
* sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis). </p>
<p>This medicine may lower the effect of the following medicines: 
* desmopressin (used to increase blood clotting factors). </p>
<p>It may still be alright for you to take these medicines and Samsca together. Your doctor will be able to 
decide what is suitable for you. </p>
<p>Samsca with food and drink 
Avoid drinking grapefruit juice when taking Samsca. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Do not take this medicine if you are pregnant or breast-feeding. </p>
<p>Adequate contraceptive measures must be used during use of this medicine. </p>
<p>Driving and using machines 
Samsca is unlikely to adversely affect your ability to drive or to operate machinery. However, you 
may occasionally feel dizzy or weak or you may faint for a short period. </p>
<p>Samsca contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<ul>
<li>Treatment with Samsca will be initiated in hospital. </li>
<li>For treatment of your low sodium (hyponatremia), your doctor will start with a dose of 15 mg 
and may then increase it to a maximum of 60 mg to achieve the desired level of serum sodium. 
To monitor the effects of Samsca your doctor will do regular blood tests. To achieve the desired 
level of serum sodium your doctor can give in some instances a lower dose of 7.5 mg. </li>
<li>Swallow the tablet without chewing, with a glass of water. </li>
<li>Take the tablets once a day preferably in the morning with or without food. </li>
</ul>
<p>If you take more Samsca than you should 
If you have taken more tablets than your prescribed dose, drink plenty of water and contact your 
doctor or your local hospital immediately. Remember to take the medicine pack with you so that it 
is clear what you have taken. </p>
<p>If you forget to take Samsca 
If you forget to take your medicine, you have to take the dose as soon as you remember on the same 
day. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a 
double dose to make up for a forgotten dose. </p>
<p>If you stop taking Samsca 
If you stop taking Samsca this may lead to reoccurrence of your low sodium. Therefore, you should 
only stop taking Samsca if you notice side effects requiring urgent medical attention (see section 4) or 
if your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>If you notice any of the following side effects, you may need urgent medical attention. Stop 
taking Samsca and immediately contact a doctor or go to the nearest hospital if you: </p>
<ul>
<li>find it difficult to urinate </li>
<li>find a swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or 
breathlessness (symptoms of an allergic reaction). </li>
</ul>
<p>Consult your doctor if symptoms of fatigue, loss of appetite, right upper abdominal discomfort, dark<br />
urine or jaundice (yellowing of skin or eyes) occur. </p>
<p>Other side effects </p>
<p>Very common (may affect more than 1 in 10 people) 
* feeling sick 
* thirst 
* rapid rise in level of sodium. </p>
<p>Common (may affect up to 1 in 10 people) 
* excessive drinking of water 
* water loss 
* high levels of sodium, potassium, creatinine, uric acid and blood sugar 
* decrease in level of blood sugar 
* decreased appetite 
* fainting 
* headache 
* dizziness 
* low blood pressure when standing up 
* constipation 
* diarrhoea 
* dry mouth 
* patchy bleeding in the skin 
* itching 
* increased need to urinate, or to urinate more frequently 
* tiredness, general weakness 
* fever 
* general feeling of being unwell 
* blood in urine 
* raised levels of liver enzymes in the blood 
* raised levels of creatinine in the blood. </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* sense of taste altered 
* kidney problems </p>
<p>Not known (cannot be estimated from the available data) 
* allergic reactions (see above) 
* liver problems 
* acute liver failure (ALF) 
* increase in liver enzymes. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Store in the original package in order to protect from light and moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Samsca contains 
* The active substance is tolvaptan 
Each Samsca 7.5 mg tablet contains 7.5 mg tolvaptan. 
Each Samsca 15 mg tablet contains 15 mg tolvaptan. 
Each Samsca 30 mg tablet contains 30 mg tolvaptan. </p>
<ul>
<li>The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, 
hydroxypropylcellulose, magnesium stearate, indigo carmine aluminium lake (E 132). </li>
</ul>
<p>What Samsca looks like and contents of the pack 
Samsca 7.5 mg: Blue, rectangular, shallow-convex tablets with dimensions of 7.7   4.35   2.5 mm, 
debossed with  OTSUKA  and  7.5  on one side. 
Samsca 15 mg: Blue, triangular, shallow-convex tablets with dimensions of 6.58   6.2   2.7 mm, 
debossed with  OTSUKA  and  15  on one side. 
Samsca 30 mg: Blue, round, shallow-convex tablets with dimensions of  8   3.0 mm, debossed with 
 OTSUKA  and  30  on one side. </p>
<p>Samsca 7.5 mg tablets are available as 
10 tablets in PP/Alu blisters 
30 tablets in PP/Alu blisters 
10   1 tablet in PVC/Alu perforated unit dose blisters 
30   1 tablet in PVC/Alu perforated unit dose blisters </p>
<p>Samsca 15 mg and Samsca 30 mg tablets are available as 
10   1 tablet in PVC/Alu perforated unit dose blisters 
30   1 tablet in PVC/Alu perforated unit dose blisters </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT, Amsterdam 
Netherlands  </p>
<p>Manufacturer 
Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YDIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
T l/Tel: +31 (0) 20 85 46 Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Te : +31 (0) 20 85 46 Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
Tel/ T l: +31 (0) 20 85 46  esk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Magyarorsz g 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528 Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Deutschland 
Otsuka Pharma GmbH 
Tel: +49691 700 Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46  sterreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Espa a 
Otsuka Pharmaceutical S.A 
Tel: +3493 2081 Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 France 
Otsuka Pharmaceutical France SAS 
T l: +33147 080 Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Rom nia 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46  sland 
Otsuka Pharma Scandinavia AB 
S mi: +46854 528 Slovensk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 02 00 63 27 Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Tel/ Puh: +46854 528 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46 Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46854 528 Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 This leaflet was last revised in {MM/YYYY} </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: CompositionUvEpi
Title: "Composition for samsca Package Leaflet"
Description:  "Composition for samsca Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1eb1b528e890c79700aede7e878d280f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - samsca"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Samsca </li>
<li>Sådan skal du tage Samsca </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What samsca is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What samsca is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Samsca, der indeholder det aktive stof tolvaptan, tilhører en gruppe lægemidler, der hedder 
vasopressin-antagonister. Vasopressin er et hormon, som medvirker til at forhindre væsketab i kroppen 
ved at mindske urinproduktionen. Antagonist betyder, at det forhindrer vasopressin i at tilbageholde 
vand. Dette medfører en nedsat mængde vand i kroppen, fordi urinproduktionen øges. Herved øges 
saltindholdet eller -koncentrationen i blodet. </p>
<p>Samsca bruges til at behandle meget lavt saltindhold i kroppen hos voksne. Du har fået ordineret dette 
lægemiddel, fordi du har et nedsat saltindhold i blodet, som skyldes en sygdom, der hedder SIADH 
(syndrome of inappropriate antidiuretic hormone secretion), hvor nyrerne tilbageholder for meget 
vand. Denne sygdom medfører en ureguleret produktion af hormonet vasopressin, som har medført, at 
saltindholdet i dit blod er for lavt (hyponatriæmi). Det kan føre til koncentrations- og 
hukommelsesbesvær eller besvær med at holde balancen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Samsca </p>
<ul>
<li>
<p>hvis du er allergisk over for tolvaptan eller et af de øvrige indholdsstoffer i denne medicin 
(angivet i punkt 6), eller hvis du er allergisk over for benzazepin eller benzazepinderivater 
(f.eks. benazepril, conivaptan, fenoldopammesylat eller mirtazapin) </p>
</li>
<li>
<p>hvis dine nyrer ikke fungerer (ingen produktion af urin) </p>
</li>
<li>
<p>hvis du har en sygdom, der øger saltindholdet i dit blod ("hypernatriæmi") </p>
</li>
<li>
<p>hvis du har en sygdom, der er forbundet med et meget lavt blodvolumen </p>
</li>
<li>
<p>hvis du ikke kan føle tørst </p>
</li>
<li>
<p>hvis du er gravid </p>
</li>
<li>
<p>hvis du ammer. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Samsca: </p>
<ul>
<li>
<p>hvis du ikke kan drikke nok vand, eller dit væskeindtag skal begrænses </p>
</li>
<li>
<p>hvis du har besvær med at lade vandet eller har forstørret blærehalskirtel (prostata) </p>
</li>
<li>
<p>hvis du har en leversygdom </p>
</li>
<li>
<p>hvis du tidligere har haft en allergisk reaktion over for benzazepin, tolvaptan eller andre 
benzazepinderivater (f.eks. benazepril, conivaptan, fenoldopammesylat eller mirtazapin) eller et 
af de øvrige indholdsstoffer (anført i pkt. 6) </p>
</li>
<li>
<p>hvis du har en nyresygdom, der kaldes autosomal dominant polycystisk nyresygdom (ADPKD) </p>
</li>
<li>
<p>hvis du har sukkersyge. </p>
</li>
</ul>
<p>Drik tilstrækkeligt med vand 
Samsca medfører vandtab, fordi det øger din urinproduktion. Dette vandtab kan medføre bivirkninger 
som f.eks. mundtørhed og tørst eller mere alvorlige bivirkninger såsom nyreproblemer (se punkt 4). 
Det er derfor vigtigt, at du har adgang til vand, og at du er i stand til at drikke tilstrækkelige mængder, 
når du er tørstig. </p>
<p>Børn og unge 
Samsca er ikke egnet til børn og unge (under 18 år). </p>
<p>Brug af Samsca sammen med anden medicin 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for 
nylig. Dette gælder også medicin, som ikke er købt på recept. </p>
<p>Følgende lægemidler kan øge virkningen af dette lægemiddel: </p>
<ul>
<li>
<p>ketoconazol (mod svampeinfektioner), </p>
</li>
<li>
<p>makrolide antibiotika, </p>
</li>
<li>
<p>diltiazem (behandling mod forhøjet blodtryk og brystsmerter), </p>
</li>
<li>
<p>andre produkter, der øger saltindholdet i dit blod, eller som indeholder store mængder salt. </p>
</li>
</ul>
<p>Følgende lægemidler kan reducere virkningen af dette lægemiddel: </p>
<ul>
<li>
<p>barbiturater (anvendes til behandling af epilepsi/krampeanfald og visse søvnforstyrrelser), </p>
</li>
<li>
<p>rifampicin (mod tuberkulose). </p>
</li>
</ul>
<p>Dette lægemiddel kan øge virkningen af følgende andre lægemidler: </p>
<ul>
<li>
<p>digoxin (anvendes til behandling af uregelmæssig hjerterytme og hjertesvigt), </p>
</li>
<li>
<p>dabigatranetexilat (blodfortyndende middel), </p>
</li>
<li>
<p>metformin (anvendes til at behandle diabetes), </p>
</li>
<li>
<p>sulfasalazin (anvendes til at behandle betændelse i tyktarmen eller reumatoid artritis). </p>
</li>
</ul>
<p>Dette lægemiddel kan reducere virkningen af følgende andre lægemidler: </p>
<ul>
<li>desmopressin (bruges til at øge koagulationsfaktorerne i blodet). </li>
</ul>
<p>Du kan sandsynligvis godt tage disse lægemidler sammen med Samsca. Din læge skal afgøre, hvad der 
er egnet til dig. </p>
<p>Brug af Samsca sammen med mad og drikke 
Du må ikke drikke grapefrugtjuice, når du tager Samsca. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Tag ikke dette lægemiddel, hvis du er gravid eller ammer. 
Du skal anvende sikker kontraception under behandlingen med dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Det er usandsynligt, at Samsca vil påvirke din evne til at føre motorkøretøj eller betjene maskiner. Dog 
kan 
Samsca en gang imellem få dig til at føle dig svimmel eller svag, eller du kan besvime i kort tid. </p>
<p>Samsca indeholder lactose. 
Hvis lægen har fortalt dig, at du ikke kan tåle visse sukkerstoffer, skal du kontakte lægen, før du tager 
dette lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<ul>
<li>
<p>Behandling med Samsca indledes på et hospital. </p>
</li>
<li>
<p>Hvis du behandles for for lidt salt i blodet (hyponatriæmi), vil din læge starte med at give dig en 
dosis på 15 mg og kan derefter øge den til maksimalt 60 mg for at opnå det ønskede serum-
natriumniveau. Din læge vil regelmæssigt tage blodprøver for at overvåge virkningen af 
Samsca. I nogle tilfælde kan din læge give dig en lavere dosis på 7,5 mg for at opnå det ønskede 
niveau af serum-natrium. </p>
</li>
<li>
<p>Synk tabletten hel sammen med et glas vand. </p>
</li>
<li>
<p>Tag tabletterne én gang dagligt, helst om morgenen, med eller uden mad. </p>
</li>
</ul>
<p>Hvis du har taget for meget Samsca 
Hvis du har taget flere tabletter end den ordinerede dosis, skal du straks drikke masser af vand og 
kontakte din læge eller nærmeste hospital. Husk at tage medicinens emballage med, så de ved, hvad 
du har taget. </p>
<p>Hvis du har glemt at tage Samsca 
Hvis du har glemt at tage din medicin, skal du tage dosis den samme dag, så snart du husker det. Hvis 
du glemmer at tage din tablet den ene dag, skal du tage den normale dosis den følgende dag. Du må 
ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Samsca 
Hvis du holder op med at tage Samsca, kan det medføre, at du igen får for lidt salt i blodet. Derfor bør 
du kun holde op med at tage Samsca, hvis du får bivirkninger, der kræver akut lægehjælp (se pkt. 4), 
eller hvis din læge har sagt, at du skal stoppe. </p>
<p>Spørg lægen eller på apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Disse bivirkninger kan forekomme med en vis hyppighed, som er defineret på følgende måde: </p>
<p>Hvis du bemærker en eller flere af følgende bivirkninger, kan du have brug for akut lægehjælp. 
Hold straks op med at tage Samsca og kontakt en læge eller nærmeste hospital, hvis du: </p>
<ul>
<li>
<p>har svært ved at lade vandet </p>
</li>
<li>
<p>opdager en hævelse i ansigtet, på læberne eller på tungen, hvis du har kløe, generaliseret udslæt, 
hvæsende vejrtrækning eller åndenød (symptomer på en allergisk reaktion). </p>
</li>
</ul>
<p>Søg læge, hvis du oplever symptomer som træthed, appetitløshed, smerter i den øvre, højre del af 
maven, mørk urin eller gulsot (gulfarvning af hud og øjne). </p>
<p>Andre bivirkninger </p>
<p>Meget almindelig (kan påvirke flere end 1 ud af 10 brugere) </p>
<ul>
<li>
<p>kvalme </p>
</li>
<li>
<p>tørst </p>
</li>
<li>
<p>hurtig stigning i natriumniveauet. </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 brugere) </p>
<ul>
<li>
<p>indtagelse af store mængder vand </p>
</li>
<li>
<p>vandtab </p>
</li>
<li>
<p>højt indhold af natrium, kalium, kreatinin, urinsyre og sukker i blodet </p>
</li>
<li>
<p>nedsat blodsukker </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>besvimelse </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>lavt blodtryk, når du rejser dig </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>mundtørhed </p>
</li>
<li>
<p>pletvis blødning i huden </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>større behov for at lade vandet eller for at lade vandet oftere </p>
</li>
<li>
<p>træthed, almen svaghed </p>
</li>
<li>
<p>feber </p>
</li>
<li>
<p>generel følelse af utilpashed </p>
</li>
<li>
<p>blod i urinen </p>
</li>
<li>
<p>forhøjede niveauer af leverenzymer i blodet </p>
</li>
<li>
<p>forhøjede niveauer af kreatinin i blodet. </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 brugere) </p>
<ul>
<li>
<p>ændret smagssans </p>
</li>
<li>
<p>nyreproblemer. </p>
</li>
</ul>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data) </p>
<ul>
<li>
<p>allergiske reaktioner (se ovenfor) </p>
</li>
<li>
<p>leverproblemer </p>
</li>
<li>
<p>akut leversvigt </p>
</li>
<li>
<p>forhøjede leverenzymer. </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store samsca"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store samsca"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, som står på pakningen og blisterpakken efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i den originale yderpakning for at beskytte mod lys og fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Samsca indeholder: </p>
<ul>
<li>
<p>Aktivt stof: Tolvaptan. 
Samsca 7,5 mg tabletter: Hver tablet indeholder 7,5 mg tolvaptan. 
Samsca 15 mg tabletter: Hver tablet indeholder 15 mg tolvaptan. 
Samsca 30 mg tabletter: Hver tablet indeholder 30 mg tolvaptan. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: Lactosemonohydrat, majsstivelse, mikrokrystallinsk cellulose, 
hydroxypropylcellulose, magnesiumstearat, indigocarmin aluminium lake (E 132). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Samsca 7,5 mg: Blå, rektangulær, flad, konveks tablet med størrelsen 7,7 × 4,35 × 2,5 mm præget med 
“OTSUKA" og “7.5" på den ene side. 
Samsca 15 mg: Blå, trekantet, flad, konveks tablet med størrelsen 6,58 × 6,2 × 2,7 mm præget med 
“OTSUKA" og “15" på den ene side. 
Samsca 30 mg: Blå, rund, flad, konveks tablet med størrelsen Ø 8 × 3,0 mm præget med “OTSUKA" 
og “30" på den ene side. </p>
<p>Samsca 7,5 mg tabletter fås som 
10 tabletter i blister af PP/alu 
30 tabletter i blister af PP/alu 
10 × 1 tablet i perforeret enkeltdosisblister af PVC/alu 
30 × 1 tablet i perforeret enkeltdosisblister af PVC/alu </p>
<p>Samsca 15 mg tabletter og Samsca 30 mg tabletter fås som 
10 × 1 tablet i perforeret enkeltdosisblister af PVC/Alu 
30 × 1 tablet i perforeret enkeltdosisblister af PVC/Alu </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT, Amsterdam 
Holland </p>
<p>Fremstiller 
Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YDIrland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
Tél/Tel: +31 (0) 20 85 46<br />
Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 България 
Otsuka Pharmaceutical Netherlands B.V. 
Teл: +31 (0) 20 85 46<br />
Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
Tel/ Tél: +31 (0) 20 85 46<br />
Česká republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Magyarország 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528<br />
Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Deutschland 
Otsuka Pharma GmbH 
Tel: +49691 700<br />
Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528<br />
Ελλάδα 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Österreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
España 
Otsuka Pharmaceutical S.A 
Tel: +3493 2081<br />
Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 France 
Otsuka Pharmaceutical France SAS 
Tél: +33147 080<br />
Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
România 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ísland 
Otsuka Pharma Scandinavia AB 
Sími: +46854 528<br />
Slovenská republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 02 00 63 27<br />
Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Tel/ Puh: +46854 528<br />
Κύπρος 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46854 528<br />
Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46  </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for samsca Package Leaflet for language en"
Description: "ePI document Bundle for samsca Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-20187f2efcc8af1ff62d82a63aba8a40"
* entry[0].resource = composition-en-20187f2efcc8af1ff62d82a63aba8a40

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp20187f2efcc8af1ff62d82a63aba8a40"
* entry[=].resource = mp20187f2efcc8af1ff62d82a63aba8a40
                            
                    
Instance: bundlepackageleaflet-da-20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for samsca Package Leaflet for language da"
Description: "ePI document Bundle for samsca Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-20187f2efcc8af1ff62d82a63aba8a40"
* entry[0].resource = composition-da-20187f2efcc8af1ff62d82a63aba8a40

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp20187f2efcc8af1ff62d82a63aba8a40"
* entry[=].resource = mp20187f2efcc8af1ff62d82a63aba8a40
                            
                    



Instance: mp20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Samsca 7.5 mg tablets"
Description: "Samsca 7.5 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Samsca 7.5 mg tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Samsca 7.5 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 20187f2efcc8af1ff62d82a63aba8a40ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "samsca"

* status = #current
* mode = #working

* title = "List of all ePIs associated with samsca"

* subject = Reference(mp1eb1b528e890c79700aede7e878d280f)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#samsca "samsca"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-20187f2efcc8af1ff62d82a63aba8a40) // samsca en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-20187f2efcc8af1ff62d82a63aba8a40) // samsca da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-20187f2efcc8af1ff62d82a63aba8a40
InstanceOf: List

* insert 20187f2efcc8af1ff62d82a63aba8a40ListRuleset
    